Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an
additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.